One item I overlooked was working capital $1.675M, as like most others CET funding was the prime focus.
So has funding in DX arena been shuftied into this bucket?
Anyway if would be good to hear if Anteotech NXT has been picked up in the Immunothearpy CAR T field of studies. I believe that Binder application is a pivotal part in CAR T thearpy outcomes.
ADO Price at posting:
2.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)